Navigation Links
Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections
Date:9/4/2008

ZURICH, Switzerland, September 4 /PRNewswire/ -- Axentis Pharma AG has initiated a clinical phase IIa trial to assess the safety and tolerability of a new therapeutic formulation for the treatment of severe pulmonary infection in cystic fibrosis patients. The new formulation allows an established therapeutic agent to be delivered directly to the site of infection. The forthcoming trial will also compare the effects of two different doses of the new drug. Initial results are expected in summer 2009. Axentis Pharma acquired all the necessary rights for this formulation from international partners just eight months ago. In addition to these advances, the company has also succeeded in appointing two renowned experts to its Scientific Advisory Board.

Axentis Pharma AG (Switzerland) announced today that all the necessary requirements for a clinical phase IIa trial have been fulfilled. The objective of this trial is to assess the safety and tolerability of an inhalable tobramycin, a well characterised and established drug for the treatment of pulmonary infection in cystic fibrosis patients. The product ARB-CF0223 ­ also known as Fluidosome(R) tobramycin ­ is a liposomal formulation of tobramycin, delivered directly to the site of infection via standard nebulizers. ARB-CF0223 has an improved safety profile and higher efficacy compared to current treatments for infections of the respiratory tract in patients with cystic fibrosis. It can be used in lower doses and also reduces the frequency and severity of side effects for pulmonary infections. The company expects to begin recruiting patients at its four international trial centres by the end of the year.

Dr. Hans Schreier, Chief Scientist of Axentis Pharma on the advances the company has made: "It was only very recently that we obtained all the necessary legal rights including transfer of sponsorship of the EMEA Orphan Designation to further develop our current lead product, Fluidosome(R) tobramycin. How
'/>"/>

SOURCE Axentis Pharma AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Promising Cystic Fibrosis Compound on Track for Development
2. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
3. Pediatric Pulmonary Expert Comments on Study of Lung Transplants for Cystic Fibrosis
4. Cystic Fibrosis Foundation Reports Upward Trend for Key Health Outcomes
5. Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF
6. Lung Transplants in Cystic Fibrosis Patients With Life-Threatening Bacteria Sparks Debate at ISHLT Meeting
7. PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis
8. PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
9. Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections
10. Mpex Initiates a Phase 2 Clinical Trial of Aerosol MP-376 in the Treatment of Chronic Bacterial Infections in Cystic Fibrosis Patients
11. The Ocean Becomes a Pipeline To A Cure for Cystic Fibrosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Fla. , July 30, 2014  Today the US ... indoor and outdoor sun tanning or sun burns stating they ... statement Surgeon, General Boris Lushniak , says that "skin ... types and that too much exposure to indoor and outdoor ... for Dermatology and Aesthetic Medicine, in Boca Raton, ...
(Date:7/30/2014)... , July 30, 2014  El Camino Hospital, a ... care, is utilizing the Leaf Patient Monitoring system to ... and movement of patients susceptible to bed sores. ... month-long, 138-patient study of the system, which showed dramatic ... Turning patients regularly is the one of the most ...
(Date:7/30/2014)... YORK , July 30, 2014 ... is available in its catalogue: mHealth ... http://www.reportlinker.com/p0356852/mHealth-and-Home-Monitoring-–-6th-Edition.html Executive summary ... are delivered, leading to better outcomes, decreased costs ... market for mHealth solutions is still in an ...
Breaking Medicine Technology:Indoor and Outdoor Sun Tanning or Sun Burns Directly Linked to Deadly Melanoma Skin Cancer 2El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 2El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 3mHealth and Home Monitoring - 6th Edition 2mHealth and Home Monitoring - 6th Edition 3mHealth and Home Monitoring - 6th Edition 4mHealth and Home Monitoring - 6th Edition 5mHealth and Home Monitoring - 6th Edition 6mHealth and Home Monitoring - 6th Edition 7mHealth and Home Monitoring - 6th Edition 8mHealth and Home Monitoring - 6th Edition 9mHealth and Home Monitoring - 6th Edition 10mHealth and Home Monitoring - 6th Edition 11
... Pharmaceuticals, Inc. (NYSE Amex: INO ), a ... against cancers and infectious diseases, has expanded its scientific ... in the fields of vaccines and cancer immunotherapeutics. Joining ... Professor of the Scripps Research Institute and founder of ...
... The Board of Directors of MSA (NYSE: MSA ... President of the company, responsible for Global Product Leadership.  Dr. ... 1, will assume the role of President of MSA International, ... his new role, Dr. Muschter will become a member of ...
Cached Medicine Technology:Inovio Pharmaceuticals Adds Two Medical Innovators to Its Scientific Advisory Board 2Inovio Pharmaceuticals Adds Two Medical Innovators to Its Scientific Advisory Board 3Inovio Pharmaceuticals Adds Two Medical Innovators to Its Scientific Advisory Board 4Inovio Pharmaceuticals Adds Two Medical Innovators to Its Scientific Advisory Board 5MSA Elects Dr. Thomas Muschter to Vice President 2
(Date:7/30/2014)... Researchers at the Monterey Bay Aquarium Research Institute (MBARI) ... four and one half yearslonger than any other known ... clean and guarded them from predators. This amazing feat ... the young octopuses of having plenty of time to ... survive for years with little or no food. , ...
(Date:7/30/2014)... 30, 2014 Frozen shoulder (Adhesive capsulitis) affects ... to develop this nasty condition which occurs most frequently in ... last up to two and half years if not treated. ... and with good reason: it can render your shoulder so ... is, if you aren't in too much pain to get ...
(Date:7/30/2014)... (HealthDay News) -- For patients with asthma, just believing ... airway inflammation for at least 24 hours, a new ... but also what you think you smell," study author ... in Philadelphia, said in a Monell news release. ... When we expect that an odor is harmful, our ...
(Date:7/30/2014)... --,Although the vast majority of kids with autism have ... differently from children who have trouble processing sensory stimuli, ... can be overly sensitive to sound, sight and touch. ... a lack of concentration. Complicating matters, some kids ... have trouble tolerating loud noises, like a vacuum. Others ...
(Date:7/30/2014)... adults who were breastfed for three months or ... of chronic inflammation associated with cardiovascular and metabolic ... at Washington University in St. Louis. , "This ... implications for children,s health decades later," said Molly ... School and a co-author of the study with ...
Breaking Medicine News(10 mins):Health News:Deep-sea octopus broods eggs for over 4 years -- longer than any known animal 2Health News:Deep-sea octopus broods eggs for over 4 years -- longer than any known animal 3Health News:Good News for Diabetics Suffering from Frozen Shoulder 2Health News:Good News for Diabetics Suffering from Frozen Shoulder 3Health News:Good News for Diabetics Suffering from Frozen Shoulder 4Health News:Even Thinking an Odor is Harmful May Spur Asthma Symptoms 2Health News:Different Areas of Brain Affected in Autism, Sensory Disorders 2Health News:Different Areas of Brain Affected in Autism, Sensory Disorders 3Health News:Birthweight and breastfeeding have implications for children's health decades later 2
... ... Dr. Howard Herman, M.D., a physician with the Atlanta Snoring Institute, ... importance of paying attention to sinus pain in order to prevent infection, ... nose, and throat doctor and head and neck surgeon at the Atlanta ...
... ... Hearing Healthcare Provider , ... Bonita Springs, FL (PRWEB) October 28, 2009 -- PHSI (Physician Hearing ... ophthalmologists with the tools needed to care for an ever-growing demographic of patients. ...
... ... platforms , ... -- New York Merchants Protective Co., Inc. , is proud to announce it will ... . , , , , ,NYMPC has been approved as an authorized Geutebruck solutions provider, ...
... , OAK BROOK, Ill., Oct. 28 Understanding the ... for health care providers, including enhancing safety and helping ... malpractice litigation. In fact, many academic medical centers are ... to improve the quality of care for patients. ...
... 27 Addus HomeCare Corporation announced today that it has ... common stock at $10.00 per share. Addus shares will ... Market under the ticker symbol "ADUS". The closing of ... 2009. Addus expects to receive net proceeds from the ...
... , TUESDAY, Oct. 27 (HealthDay News) -- Combining chemotherapy ... neck cancer increases their event-free survival to 2.2 years ... new study. , According to the study authors, "events" ... researchers looked at the 10-year outcomes of 966 patients ...
Cached Medicine News:Health News:Atlanta Snoring Institute Doctor Provides Expert Advice on Relief of Flu Symptoms and Prevention of Sinus Infection 2Health News:Atlanta Snoring Institute Doctor Provides Expert Advice on Relief of Flu Symptoms and Prevention of Sinus Infection 3Health News:Atlanta Snoring Institute Doctor Provides Expert Advice on Relief of Flu Symptoms and Prevention of Sinus Infection 4Health News:PHSI, INC. Develops Revolutionary Vision-Hearing Program 2Health News:New York Merchants Protective Co. Designated as Authorized Geutebruck Solutions Provider 2Health News:New York Merchants Protective Co. Designated as Authorized Geutebruck Solutions Provider 3Health News:UHC Benchmarking Project Focuses on Patient- and Family-Centered Care in Academic Medical Centers 2Health News:UHC Benchmarking Project Focuses on Patient- and Family-Centered Care in Academic Medical Centers 3Health News:Addus HomeCare Corporation Prices Initial Public Offering 2Health News:Adding Chemo Helps Head, Neck Cancer Patients 2
... Enzyme-linked immunosorbent assay method for ... autoantibodies to myeloperoxidase in human serum. ... can be used as an aid ... and other conditions associated with elevated ...
... of this Enzyme ImmunoAssay (EIA) is as ... immobilised on a 96 well microtiter plate. ... washing, the trapped molecule is covalently linked ... groups. After washing and denaturing treatment, Angiotensin ...
... determination of Ang II is ... the pharmacological effect and efficiency ... angiotensin converting enzyme inhibitors (ACE ... antagonists as well as for ...
Anti-RSV IgA Assay (ELISA)....
Medicine Products: